[Rational pharmacotherapy of patients with coronory heart disease combined with anxiety disorders].

The aim of the study was to evaluate the efficacy and safety of combined usage of Vazonat and Adaptol in patients with coronary heart disease (CHD) and anxiety disorders. It was shown that the use of a modulator metabolism Vasonat in addition to conventional therapy promotes CHD clinical improvement and increased myocardial contractility. The therapy in most patients there was a significant reduction in the intensity of anxiety symptoms, improve general health and mood. In addition to improved parameters of psychiatric sphere yhere was positive dynamics for somatisation disorders and autonomic manifestations of pain in patients with CHD and anxiety disorders.

[Optimization of energy metabolism in patients with chronic heart failure].

Nowadays particular interest of clinicians is attracted by metabolic therapy of patients with chronic heart failure (CHF). The objective of this study was to investigate the influence of complex therapy with addition of Vasonat on the dynamics of remodeling indexes of left ventricle and functional class of CHF on classification of NYHA. It has been shown that application of metabolic modulator Vasonat in addition to conventional therapy of CHF facilitated the clinical improvement and significant decline of functional class. Vasonat use resulted in the meaningful improvement of the contractive function of myocardium and increase of tolerance to the physical exercise. Moreover, high efficiency of Vasonat has been demonstrated in the control of the syndrome of oxidizing stress, by decrease in intensity of free-radical processes and activation of the antioxidant defense system.

[Clinical and metabolic effects of betaxolol (lokren) in treatment of patients with chronic cardiac insufficiency]. / Klinicheskie i metabolicheskie éffekty betaksolola (lokrena) pri lechenii bol'nykh s khronicheskoi serdechnoi nedostatochnost'iu.

Effects were studied of a selective beta-adrenoblocker betaxolol on clinical, hemodynamic, and metabolic indices in patients with chronic cardiac insufficiency (ChCI). A total of 47 patients (27 men and 20 women) with functional class II-III ChCI by the classification of the New-York Association of Cardiologists and the left ventricular ejection fraction less than 40% were examined. The use of betaxolol in the conventional therapy of ChCI has been shown to be of significant clinical benefit in the above patient population, with the improvement in hemodynamic status, the functional class exercise-induces angina alleviated, the left ventricular ejection fraction significantly became greater. Moreover, long-term treatment with betaxolol tends to lower the degree of lipid peroxidation with no adverse effect being exerted on lipid and carbohydrate metabolism.

[Effects of inhibitors of angiotensin-converting enzyme combined with antagonists of angiotensin II receptors on endothelial function in patients with chronic cardiac insufficiency]. / Vliianye ingibitorov angiotenzinprevrashchaiushchego fermenta v sochetanii s antagonistami retseptorov angiotenzina II na funktsional'noe sostoianie endoteliia u bol'nykh s khronicheskoi serdechnoi nedostatochnost'iu.

Effects were studied of a combined therapy with inhibitors of the angiotensin-converting enzyme and antagonists of receptors to angiotensin II on the functional condition of the endothelium in patients with chronic cardiac insufficiency (CCI). Recordable in the study was a noticeable decrease in the level of endothelin-1 and higher values for the concentration of 6-keto-prostaglandin (PGF1 alpha) and cGMP. In that way, administration of inhibitors of the angiotensin-converting enzyme combined with antagonists of receptors to angiotensin II has, been shown to considerably improve the endothelial function in CCi patients, which fact will, we believe, help in raising clinical effectiveness of the above combined medication.

[The effect of angiotensin-II receptor antagonists on the vasoconstriction mechanisms in chronic heart failure]. / Vliianie antagonistov retseptorov angiotenzina II na mekhanizmy vazokonstriktsii pri khronicheskoi serdechnoi nedostatochnosti.

Overall thirty-two patients with chronic heart failure (CHF) II-IV FC according to NYHA classification were studied for effects of irbesartan, an antagonist of receptors to angiotensine II on mechanisms of vasoconstriction. Noted as a result of the treatment conducted was a significant reduction in the content of vasoconstrictors of angiotensin II, vasopressin, and epinephrine as well as a tendency toward decrease in values for thromboxane A2 and adrenaline. Vasoconstrictor factors were found to have an important part in vascular control in realization of efficacy of irbesartan, an antagonist of receptors to angiotensin II, in CHF patients.